Zafgen Inc. (ZFGN) Reaches New 1-Year Low at $3.06
Zafgen Inc. (NASDAQ:ZFGN)’s share price reached a new 52-week low during trading on Thursday . The company traded as low as $3.06 and last traded at $3.07, with a volume of 2,113,409 shares traded. The stock had previously closed at $3.24.
ZFGN has been the subject of a number of research analyst reports. FBR & Co reiterated a “buy” rating and set a $20.00 price target on shares of Zafgen in a report on Monday, April 4th. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Thursday, May 12th. Leerink Swann reiterated a “hold” rating and set a $6.00 price target on shares of Zafgen in a report on Monday, April 11th. Canaccord Genuity set a $4.00 price target on Zafgen and gave the stock a “hold” rating in a report on Thursday. Finally, Cowen and Company cut Zafgen from an “outperform” rating to a “market perform” rating in a report on Wednesday. Six research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Zafgen has a consensus rating of “Hold” and an average target price of $9.69.
The firm’s market capitalization is $80.45 million. The firm’s 50 day moving average price is $6.07 and its 200-day moving average price is $6.51.
Zafgen (NASDAQ:ZFGN) last posted its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.09. During the same quarter last year, the business posted ($0.53) earnings per share. Analysts predict that Zafgen Inc. will post ($2.64) EPS for the current year.
Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.